Meyahealth
HomeGeneticsGeneGP1BA gene
Back to Gene
GP1BA gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

GP1BA gene

The GP1BA gene provides instructions for making a protein essential for blood clotting by allowing platelets to bind to injured blood vessels.

Normal Function

The GP1BA gene provides instructions for making a protein called glycoprotein Ib-alpha (GPIbα). This protein is one piece (subunit) of a protein complex called GPIb-IX-V, which plays a role in blood clotting. GPIb-IX-V is found on the surface of small cells called platelets, which circulate in blood and are an essential component of blood clots.

The complex can attach (bind) to a protein called von Willebrand factor, fitting together like a lock and its key. Von Willebrand factor is found on the inside surface of blood vessels, particularly when there is an injury. Binding of the GPIb-IX-V complex to von Willebrand factor allows platelets to stick to the blood vessel wall at the site of the injury. These platelets form clots, plugging holes in the blood vessels to help stop bleeding.

To form the GPIb-IX-V complex, GPIbα interacts with other protein subunits called GPIb-beta, GPIX, and GPV, each of which is produced from a different gene. GPIbα is essential for assembly of the complex at the platelet surface. It is the piece of the complex that interacts with von Willebrand factor to trigger blood clotting. GPIbα also interacts with other blood clotting proteins to aid in other steps of the clotting process.

Health Conditions Related to Genetic Changes

Bernard-Soulier syndrome

At least 54 GP1BA gene mutations have been found to cause Bernard-Soulier syndrome, a condition characterized by a reduced number of platelets that are larger than normal (macrothrombocytopenia) and excessive bleeding. Some of these mutations lead to production of an altered GPIbα subunit that is likely broken down too soon or that cannot get to the platelet surface. Lack of this subunit on the surface of platelets prevents formation of the GPIb-IX-V complex. Without GPIb-IX-V, platelets cannot come together at the site of an injury to form a clot, leading to the bleeding problems associated with Bernard-Soulier syndrome. Other mutations lead to production of a subunit that can form GPIb-IX-V complexes but cannot interact with von Willebrand factor, which also impairs the accumulation of platelets necessary for clotting.

Other disorders

At least six mutations in the GP1BA gene can cause another bleeding disorder called platelet-type von Willebrand disease (also known as pseudo-von Willebrand disease). This disorder is characterized by a reduced number of platelets in the blood (thrombocytopenia) and mild bleeding abnormalities. In contrast to mutations that cause Bernard-Soulier syndrome, mutations involved in platelet-type von Willebrand disease lead to excessive binding of the GPIb-IX-V complex to von Willebrand factor. Because platelets containing the altered complex attach to von Willebrand factor without an injury to the blood vessel, fewer platelets are available for clot formation when an injury occurs, which leads to excessive bleeding.

Other Names for This Gene

  • antigen CD42b-alpha
  • BDPLT1
  • BDPLT3
  • BSS
  • CD42B
  • CD42b-alpha
  • DBPLT3
  • glycoprotein Ib (platelet), alpha polypeptide
  • glycoprotein Ib platelet alpha subunit
  • GP-Ib alpha
  • GP1B
  • GPIbA
  • GPIbalpha
  • platelet glycoprotein Ib alpha chain precursor
  • platelet membrane glycoprotein 1b-alpha subunit
  • VWDP

Frequently Asked Questions

Long‑term strategies focus on avoiding trauma, using protective gear during sports, and maintaining a healthy diet rich in vitamin K to support clotting. Some patients benefit from prophylactic platelet transfusions before major surgeries. Research into gene therapy is ongoing but not yet available for routine use.
Mutations in the GP1BA gene impair the production or function of the GPIbα subunit, which is essential for assembling the GPIb‑IX‑V complex on platelet surfaces. This disruption leads to fewer platelets (thrombocytopenia) that are larger than normal (macrothrombocytes), reducing the blood’s ability to form clots efficiently.
Patients are prone to mucosal bleeding (nosebleeds, gum bleeding), prolonged bleeding after surgery or trauma, and, in severe cases, internal hemorrhage. Management includes platelet transfusions during bleeding episodes, antifibrinolytic agents (e.g., tranexamic acid) for mucosal bleeding, and careful monitoring during dental or surgical procedures.
Diagnosis involves a combination of platelet count, platelet size assessment via a blood smear, and flow cytometry to measure GPIbα expression on platelets. A platelet function test, such as ristocetin‑induced aggregation, is also performed. Genetic testing for GP1BA mutations confirms the diagnosis.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ